menu
    • menu

    Company profile for Aimmune Therapeutics

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Developing desensitization treatments to help protect people with food allergies from the potentially life-threatening consequences of accidental exposure Aimmune is a clinical-stage biopharmaceutical company developing proprietary product candidates and advancing a therapeutic approach for the treatment of peanut and other food allergies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Aimmune TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    8000 Marina Boulevard Suite 300 Brisbane, CA 94005-1884
    Telephone
    Telephone
    (650) 614-5220
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.aimmune.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nestlé reconsiders peanut allergy program two years after $2.6B buyout
    Nestlé reconsiders peanut allergy program two years after $2.6B buyout

    30 Nov 2022

    // Nicole DeFeudis ENDPTS

    https://endpts.com/nestle-reconsiders-peanut-allergy-program-two-years-after-2-6b-buyout/

    Nicole DeFeudis ENDPTS
    30 Nov 2022
    Share Share
    Aimmune to Present Positive Results from Phase 3 POSEIDON Study of PALFORZIA
    Aimmune to Present Positive Results from Phase 3 POSEIDON Study of PALFORZIA

    10 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221110005174/en

    BUSINESSWIRE
    10 Nov 2022
    Share Share
    Allergy Announces Collaboration with Aimmune Therapeutics to Provide PALFORZIA
    Allergy Announces Collaboration with Aimmune Therapeutics to Provide PALFORZIA

    13 Oct 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221013006052/en

    BUSINESSWIRE
    13 Oct 2022
    Share Share
    Aimmune Tx to Present New Data for PALFORZIA at the EAACI
    Aimmune Tx to Present New Data for PALFORZIA at the EAACI

    30 Jun 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220630005003/en

    BUSINESSWIRE
    30 Jun 2022
    Share Share
    Egg allergy trials halted by Aimmune; Atlas closes its 13th fund for $450M
    Egg allergy trials halted by Aimmune; Atlas closes its 13th fund for $450M

    03 Mar 2022

    // Josh Sullivan ENDPTS

    https://endpts.com/egg-allergy-trials-halted-by-aimmune-atlas-closes-its-13th-fund-for-450m/

    Josh Sullivan ENDPTS
    03 Mar 2022
    Share Share
    Aimmune to Publish Pooled Safety Analysis of PALFORZIA Treatment up to 2 Years
    Aimmune to Publish Pooled Safety Analysis of PALFORZIA Treatment up to 2 Years

    16 Feb 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220216005945/en

    BUSINESSWIRE
    16 Feb 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search